ETV1 transcriptional manipulation of KIFC1 regulates the progression of pancreatic cancer.

IF 2 4区 医学 Q3 ONCOLOGY
Oncology Research Pub Date : 2025-06-26 eCollection Date: 2025-01-01 DOI:10.32604/or.2025.059631
Fangfang Hu, Zhibin Bai, Yang Wang, Haodong Tang, Jiahua Zhou
{"title":"ETV1 transcriptional manipulation of KIFC1 regulates the progression of pancreatic cancer.","authors":"Fangfang Hu, Zhibin Bai, Yang Wang, Haodong Tang, Jiahua Zhou","doi":"10.32604/or.2025.059631","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Kinesin-14 family protein 1 (KIFC1) is abnormally overexpressed in various cancers, and the transcription factor ETS variant 1 (ETV1) is an oncogenic transcription factor in tumors. The potential binding sites on the KIFC1 promoter by ETV1 were observed; however, no evidence supports that ETV1 targets KIFC1. Aims: This study aimed to investigate the relationship between KIFC1 and ETV1, and their effects and mechanisms in pancreatic cancer.</p><p><strong>Methods: </strong>Pan-cancer analysis of KIFC1 expression was performed in GEPIA2 database. KIFC1 expression levels were determined by immunohistochemistry (IHC) in our pancreatic cancer cohort. The correlation between KIFC1 expression and prognosis, tumor mutation burden, tumor purity, mismatch repair, and high-frequency tumor mutated genes was analyzed using a series of bioinformatic tools. ETV1 targeting of KIFC1 promoter transcription was determined using luciferase reporter assay. KIFC1 knockdown and ETV1 overexpression were used to determine the role of the ETV1/KIFC1 axis in cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of pancreatic cancer cells <i>in vitro</i> and tumor growth <i>in vivo</i>.</p><p><strong>Result: </strong>KIFC1 expression was increased in clinical specimens and pancreatic cancer cell lines and positively correlated with tumor mutation burden, tumor purity, mismatch repair, and KRAS and TP53 mutations. High KIFC1 expression was significantly associated with poor prognosis. Knockdown of KIFC1 suppressed the proliferation, migration, and invasion of pancreatic cancer cells and tumor growth. ETV1 overexpression increased KIFC1 expression and affected KIFC1 transcription. ETV1 overexpression reversed the role of KIFC1 knockdown in inhibiting cell proliferation, invasion, migration, and EMT, as validated <i>in vivo</i>.</p><p><strong>Conclusions: </strong>KIFC1 serves as a tumor activator in pancreatic cancer by promoting proliferation, migration, invasion, and tumor growth, which may be partly manipulated by ETV1.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"33 7","pages":"1723-1737"},"PeriodicalIF":2.0000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215546/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32604/or.2025.059631","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Kinesin-14 family protein 1 (KIFC1) is abnormally overexpressed in various cancers, and the transcription factor ETS variant 1 (ETV1) is an oncogenic transcription factor in tumors. The potential binding sites on the KIFC1 promoter by ETV1 were observed; however, no evidence supports that ETV1 targets KIFC1. Aims: This study aimed to investigate the relationship between KIFC1 and ETV1, and their effects and mechanisms in pancreatic cancer.

Methods: Pan-cancer analysis of KIFC1 expression was performed in GEPIA2 database. KIFC1 expression levels were determined by immunohistochemistry (IHC) in our pancreatic cancer cohort. The correlation between KIFC1 expression and prognosis, tumor mutation burden, tumor purity, mismatch repair, and high-frequency tumor mutated genes was analyzed using a series of bioinformatic tools. ETV1 targeting of KIFC1 promoter transcription was determined using luciferase reporter assay. KIFC1 knockdown and ETV1 overexpression were used to determine the role of the ETV1/KIFC1 axis in cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of pancreatic cancer cells in vitro and tumor growth in vivo.

Result: KIFC1 expression was increased in clinical specimens and pancreatic cancer cell lines and positively correlated with tumor mutation burden, tumor purity, mismatch repair, and KRAS and TP53 mutations. High KIFC1 expression was significantly associated with poor prognosis. Knockdown of KIFC1 suppressed the proliferation, migration, and invasion of pancreatic cancer cells and tumor growth. ETV1 overexpression increased KIFC1 expression and affected KIFC1 transcription. ETV1 overexpression reversed the role of KIFC1 knockdown in inhibiting cell proliferation, invasion, migration, and EMT, as validated in vivo.

Conclusions: KIFC1 serves as a tumor activator in pancreatic cancer by promoting proliferation, migration, invasion, and tumor growth, which may be partly manipulated by ETV1.

KIFC1的ETV1转录调控胰腺癌的进展。
背景:Kinesin-14家族蛋白1 (KIFC1)在多种癌症中异常过表达,而转录因子ETS变体1 (ETV1)是肿瘤中的一种致癌转录因子。观察了ETV1在KIFC1启动子上的潜在结合位点;然而,没有证据支持ETV1靶向KIFC1。目的:本研究旨在探讨KIFC1与ETV1的关系及其在胰腺癌中的作用和机制。方法:在GEPIA2数据库中进行KIFC1泛癌表达分析。在我们的胰腺癌队列中,通过免疫组织化学(IHC)检测KIFC1表达水平。使用一系列生物信息学工具分析KIFC1表达与预后、肿瘤突变负担、肿瘤纯度、错配修复和高频肿瘤突变基因的相关性。利用荧光素酶报告基因法确定ETV1对KIFC1启动子转录的靶向性。通过KIFC1敲低和ETV1过表达,研究ETV1/KIFC1轴在体外胰腺癌细胞增殖、迁移、侵袭、上皮-间质转化(EMT)和体内肿瘤生长中的作用。结果:KIFC1在临床标本和胰腺癌细胞系中表达升高,与肿瘤突变负担、肿瘤纯度、错配修复、KRAS和TP53突变呈正相关。KIFC1高表达与预后不良显著相关。敲低KIFC1抑制胰腺癌细胞的增殖、迁移、侵袭和肿瘤生长。ETV1过表达增加KIFC1表达,影响KIFC1转录。体内实验证实,ETV1过表达逆转了KIFC1敲低在抑制细胞增殖、侵袭、迁移和EMT中的作用。结论:KIFC1通过促进胰腺癌的增殖、迁移、侵袭和肿瘤生长发挥肿瘤激活剂的作用,其作用可能部分受ETV1的调控。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncology Research
Oncology Research 医学-肿瘤学
CiteScore
4.40
自引率
0.00%
发文量
56
审稿时长
3 months
期刊介绍: Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信